MedTrace Logo

A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults

NCT07455240 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-23

No results posted yet for this study

Summary

The purpose of this study is to learn about:

* How PF-07328948 is changed and removed from the body after taking
* Safety of PF-07328948
* The extent to which undesirable effects can be tolerated after taking PF-07328948 for the possible treatment of heart failure

This study is seeking participants who:

* Are healthy Chinese adults who are aged 18 years old and older
* Have body mass index from 18.5 to under 28 kilograms/meter square
* Have a total body weight over 50 kilograms (110 pounds)
* Do not have a history of blood clots blocking an artery or vein

All participants in this study will receive oral daily PF-07328948 at the study clinic for 7 consecutive days.

The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe.

Participants will take part in this study for around 10 weeks. During this time, participants will have 1 study visit at the study clinical and 1 contact over the phone.

Conditions

  • Healthy Participant

Interventions

DRUG

PF-07328948

Oral tablet

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2026-04-15
Completion
2026-04-15

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07455240 on ClinicalTrials.gov